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INTRODUCTION
Aspirin May Be Adequate for Venous Thromboembolic Event Prophylaxis 
after Revision Hip and Knee Arthroplasty
Gregory K. Deirmengian MD, Snir Heller MD,  Eric B. Smith MD, Mitchell Maltenfort PhD,  Javad Parvizi MD, FRCS.
Investigation performed at the Rothman Institute at Thomas Jeerson University, Phladelphia, PA.
MATERIALS AND METHODS
DISCUSSION
REFERENCES
Table 2: Logistic regression analysis for the evaluation of VTE prophylaxis and other factors on the occur-
rence of any VTE, major bleeding and mortality.
VTE=Venous thromboembolic event.
 The optimal prophylaxis for prevention of venous thromboembolic events (VTE) 
after total hip arthroplasty (THA) and total knee arthroplasty (TKA) remains unknown.(1) 
Current studies focus on primary arthroplasty and there are little to no data on the ideal 
prophylaxis for VTE following revision arthroplasty.(2) Revision surgery, due to its com-
plexity, longer operative time, higher risk of bleeding and infection diers from primary 
arthroplasty.(3) The objective of this study was to evaluate whether aspirin, known to be 
eective for prevention of VTE after primary arthroplasty, is also eective against such 
events following revision THA and TKA.  
 We studied 2,997 consecutive patients who underwent revision THA and TKA and 
were treated with either aspirin (534 patients) or warfarin (2,463 patients) between 2005 
and 2013. In all patients, aspirin or warfarin was initiated immediately after the surgery 
and continued for 6 weeks. Intermittent pneumatic compression devices were applied 
immediately after the surgery and used throughout the hospital stay and patients were 
mobilized beginning the day of surgery. For patients in whom warfarin was adminis-
tered, levels were closely monitored and doses adjusted for a goal INR of 1.8-2.0.
Data on the incident of symptomatic VTE, bleeding events, and mortality were retrieved 
from our prospectively-collected database. 
Multivariate analysis was performed to isolate the role of anticoagulation in the preven-
tion of VTE and its inuence on complications.
 To our knowledge, this study is the rst of its kind to demonstrate that aspirin is a 
viable option for prevention of VTE following revision arthroplasty. Administration of 
aspirin to these patients, at worst, should be expected to reach the same ecacy as war-
farin and may reduce the risk for bleeding events. While aspirin is a viable chemopro-
phylaxis for the majority of patients, patients at much higher risk of VTE, may require 
more potent thrombophylaxis. Further research is warranted to stratify risk factors and 
identify patients at higher risk of VTE prior to surgery so that appropriate prophylaxis 
can be administered.  
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TABLES 1 & 2 FIGURE 1
 The incidence of symptomatic VTE was signicantly higher in the warfarin group at 
1.75% (43/2,463) compared with 0.56% (3/534) in the aspirin group [odds ratio (OR) 3.2; 
95% condence interval (CI)1.03-16.3; p=0.03]. Two patients (0.4%) in the aspirin group 
were diagnosed with symptomatic deep venous thrombosis (DVT) compared with 23 
(0.9%) in the warfarin group. One patient (0.2%) in the aspirin group was diagnosed with 
symptomatic pulmonary embolism (PE) compared with 24 (0.8%) in the warfarin group. 
One patient from the warfarin group had a fatal PE. There was a higher rate of bleeding 
events (either local hematoma requiring reoperation or bleeding to other organs) with 
warfarin (37 patients, 1.5%) compared with aspirin (2 patients 0.4%) (p=0.02; OR 4.1; 95% 
CI 1.2-34.0).
RESULTS
Table 1: Bivariate analysis comparing potential confounding factors for patients that had VTE with those 
that did not have VTE.
VTE=Venous thromboembolic event; BMI=Body mass index; CCI=Charlson comorbidity index; PJI=Periprosthetic 
joint infection.
* Mean (Standard Deviation)
DISCUSSION
Figure 1: The distribution of revision patients in our cohort receiving aspirin vs. warfarin
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Aspirin
Warfarin
Total
VTE No VTE p-value
Gender (male) 48.9% 45.4% 0.77
Age* 70 (11) 65 (12) 0.001
BMI* 29.5 (6.2) 30.0 (6.6) 0.56
Knee vs hip joint 45.6% 37.7% 0.36
CCI score 0 43.5% 61.0%
0.005
CCI score 1 28.3% 22.9%
CCI score 2 17.3% 9.4%
CCI (score of 3 or more) 10.9% 6.7%
Duration of surgery (minutes)* 121 (77) 122 (49) 0.38
PJI as indication 15% 10% 0.13
Odds Ratio
95% 
conﬁdence 
interval
p-value
Any VTE
Warfarin vs Aspirin 2.92 0.90-9.45 0.074
Age/year 1.04 1.01-1.06 0.0057
Charlson 
comorbidity index 1.20 1.01-1.43 0.040
Any Major 
Bleeding
Warfarin vs Aspirin 2.13 0.46-9.96 0.37
calendar year 0.86 0.75-0.99 0.042
Charlson 
comorbidity index 1.30 1.08-1.57 0.0060
Mortality
Warfarin vs Aspirin 1.09 0.13-9.25 0.93
Charlson 
comorbidity index 1.70 1.34-2.16 < 0.0001
